Taking a Deep Dive Into New Real-world Safety Data on Upadacitinib (Rinvoq, AbbVie) in AD With Dr. Christopher Bunick
New research presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France, provides compelling real-world evidence about the safety of upadacitinib (Rinvoq, AbbVie) when it comes to long-term incidence rates of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), and malignancy (excluding non-melanoma skin cancers (NMSC)). The main takeaway? MACE, […]